BGMS מכפיל P/S עתידי Bio Green Med Solution

cyclacel.com (BGMS) - לוגו תאגידי

The forward P/S ratio reflects market revenue expectations for Bio Green Med Solution Inc (BGMS), where the current parameter is 2.50. The business relies on external contractors for synthesis and testing. Targeted alliances with funds complement a strategy of standalone trials. Ultimate success is based on patent protection and the clinical trial results of targeted drugs.

BGMS (cyclacel.com) היסטוריית יחס מחיר להכנסות צפויות מ-13.09.2025 עד 13.11.2026

Cyclacel - פילוחים אנליטיים ומדדי מפתח (BGMS)

- מחיר נוכחי ושווי מניות חזוי:
ניתוח מסכם של החברה:Bio Green Med Solution (BGMS)
דוגמת מוצר של cyclacel.com

Minimizing investment risks requires an analysis of projected revenue, particularly when geopolitical barriers and disrupted medtech supply chains create revenue uncertainty for Bio Green Med Solution Inc (BGMS). The ratio of market capitalization to expected sales, as reflected in the forward P/S history, allows investors to determine the degree of overpayment for the asset and assess the impact of liquidity on the business valuation.